Skip to content
Head to head

United Therapeutics vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: UTHR · TAK

Updated 8 minutes ago

1-year performance, rebased to 100

UTHR +17.5%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
UTHRTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price554.7321.77
Change today-0.78%+1.68%
1-year return+16.9%+57.5%
Market cap$23.63B$69.76B
52-week range455.63 – 614.2313.92 – 22.07
Valuation
P/E (TTM)20.94311.00
P/E percentile, own 5-yr range96th100th
P/B3.761.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)27.86-0.30
Net profit (TTM)$1.19B$-970.94M
Revenue (TTM)$3.19B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+4.1%+6.7%
Gross margin86.3%65.8%
Operating margin39.4%14.3%
Net margin38.6%0.9%
Free cash flow (TTM)$861.70M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership104.4%51.3%
Insider activity (12mo)0 buy / 50 sell19 buy / 31 sell
Short interest (% of float)4.3%0.1%
Analyst consensus79% buy / 14% hold / 7% sell (14)100% buy (1)
Analyst price target$683 (+23%)$50 (+132%)
StockVane view
StockVane Quant RatingC (60)C (90)
Company
Employees1,40047,029
Founded19961781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.